

1 **Clinical characterization of human monkeypox infections in** 2 **the Democratic Republic of the Congo**

3 **Short Title: Clinical characterization of human monkeypox** 4 **infection**

5 Phillip R. Pittman^{1¶*}, James W. Martin^{1,2¶}, Placide Mbala Kingebeni^{3,4}, Jean-Jacques Muyembe Tamfum³,
6 Qingwen Wan¹, Mary G. Reynolds⁵, Xiaofei Quinn¹, Sarah Norris¹, Michael B. Townsend⁵, Panayampalli S.
7 Satheshkumar⁵, Bryony Soltis, Anna Honko, Fernando B. Güereña¹, Lawrence Korman¹, John W.
8 Huggins¹ on behalf of The Kole Human Monkeypox Infection Study Group[^]

9
10 ¹Division of Medicine, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort
11 Detrick, MD, USA

12 ²Walter Reed National Military Medical Center, Bethesda, MD

13 ³Institut National de Recherche Biomédicale, Ministère de la Santé Publique, Kinshasa-Gombe B.P. 1197,
14 Democratic Republic of the Congo (DRC)

15 ⁴L'Hôpital Général de Référence de Kole, Kole, Democratic Republic of the Congo

16 ⁵Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, NE, Atlanta, GA

17 [¶]Co-first authors contributed equally to this work.

18 *Corresponding author

19 E-mail: phillip.r.pittman.civ@mail.mil

20 [^]Membership of the Kole Human Monkeypox Infection Study Group is provided in the

21 Acknowledgements.

22

23 **Abstract**

24 We describe the results of a prospective observational study of the clinical natural
25 history of human monkeypox virus (MPXV) infections at the remote General Reference Hospital
26 of Kole (Kole hospital), the rainforest of the Congo River basin of the Democratic Republic of the
27 Congo (DRC) from March 2007 until August 2011. The research was conducted jointly by the
28 Institute National de Recherche Biomedical (INRB) and the US Army Medical Research Institute
29 of Infectious Diseases (USAMRIID). The Kole hospital was one of the two previous WHO
30 Monkeypox (MPX) study sites (1981-1986). The hospital is staffed by a Spanish Order of
31 Catholic Nuns from La Congregation Des Seours Missionnaires Du Christ Jesus including two
32 Spanish physicians, who were members of the Order as well, were part of the WHO study on
33 human monkeypox. Of 244 patients admitted with a clinical diagnosis of MPXV infection, 216
34 were positive in both the Pan-Orthopox and MPXV specific PCR. The cardinal observations of
35 these 216 patients are summarized in this report. There were three deaths (3/216) among
36 these hospitalized patients; fetal death occurred in 4 of 5 (80%) patients who were pregnant at
37 admission. The most common complaints were rash (96.8%), malaise (85.2%), sore throat
38 (78.2%), and lymphadenopathy/adenopathy (57.4%). The most common physical exam findings
39 were MPX rash (99.5%) and lymphadenopathy (98.6%). Age group of less than 5 years had the
40 highest lesion count. Primary household cases tended to have higher lesion counts than
41 secondary or later same household cases. Of the 216 patients, 200 were tested for IgM & IgG
42 antibodies (Abs) to Orthopoxviruses. All 200 patients had anti-orthopoxvirus IgG Abs; whereas
43 189/200 were positive for IgM. Patients with hypoalbuminemia had a high risk of severe

44 disease. Patients with fatal disease had significantly higher maximum geometric mean values
45 than survivors for the following variables, respectively: viral DNA in blood (DNAemia,
46 $p=0.0072$); maximum lesion count ($p=0.0025$); day of admission mean AST and ALT ($p=0.0002$
47 and $p = 0.0224$, respectively, adjusted p-values).

48 Author Summary: This is a prospective observational study of Human monkeypox disease, an
49 emerging infectious disease in parts of the continent of Africa. There are certain differential
50 characteristics when compared to other pox diseases. This paper describes the presenting
51 symptoms and signs of human monkeypox disease, laboratory findings and makes
52 recommendation for the medical treatment of patients with monkeypox disease.

53

54 **Introduction**

55 Monkeypox virus (MPXV), a zoonotic orthopoxvirus (OPXV), causes a potentially lethal
56 infection in humans that clinically resembles smallpox (1). Since the eradication of smallpox in
57 the 1970's (2), MPXV has been considered the OPXV posing the greatest danger to human
58 populations (3). Smallpox vaccination provides partial cross-protective immunity against human
59 monkeypox (MPX) (4-6). The cessation of routine vaccination against smallpox has left human
60 populations increasingly vulnerable to MPXV, and to variola virus (VARV, causative agent of
61 smallpox), a potential agent of biowarfare (7).

62 Historically, most cases of MPX have occurred in western and central Africa, primarily
63 the Democratic Republic of the Congo (DRC, formerly Zaïre) (3, 8, 9). Intensive surveillance for
64 human MPX from 1981 to 1986 (4) and stochastic modeling of MPXV transmission in human
65 populations concluded that human to human transmission of monkeypox did not constitute a

66 major public health problem. However, more recent active surveillance undertaken in 2005–
67 2007 demonstrated an average annual cumulative incidence of 5.53 per 10,000, a 20-fold
68 increase over 30 years (11). This finding has raised concerns over the potentially growing threat
69 posed by MPXV and other OPXVs in the context of an increasingly immunologically naïve
70 human population (12). The re-emergence of human monkeypox infection, from 2017-2019, in
71 West and Central Africa supports this proposition (13-16). Furthermore, cases of monkeypox
72 disease in humans have been imported into England, Singapore and Israel (17-19), in addition
73 to the human cases in the United States stemming from rodents imported from Ghana (20) and
74 a traveler from Nigeria to Dallas, TX (21). More recent human-to-human transmission modeling
75 of monkeypox by Grant, et al., concluded, “The geographic spread of monkeypox cases has
76 expanded beyond the forests of central Africa, where cases were initially found, to other parts
77 of the world, where cases have been imported. This transmission pattern is likely due to the
78 worldwide decline in *orthopoxvirus* immunity, following cessation of smallpox vaccination.”
79 They further used mathematical modeling to detail that “Monkeypox could therefore emerge
80 as the most important *orthopoxvirus* infection in humans... [and] the epidemic potential of
81 monkeypox will continue increasing” (22).

82 The original intent of the study was to obtain human MPX infection data to include such
83 parameters as lesion counts, levels of viremia and basic clinical lab tests to compare human
84 MPX infection to various orthopox infection animal models of human smallpox. Since this study
85 was initiated researchers have developed an approved treatment for variola; however, the
86 continued use of such animal models will be important in exploration of additional therapeutic

87 options for smallpox. The biodefense community recognizes a need for continued therapeutics
88 development in the event of VARV reintroduction to the world as a human infection.

89 A greater understanding of human MPXV infection will aid efforts to protect human
90 populations from the threat posed by MPXV as well as the potential threat posed by VARV (23).
91 In this study, we sought to improve understanding of the clinical course of human MPXV
92 infection which will be crucial for the continued development of therapeutic interventions
93 against human OPXV infections.

94

95 **Methods**

96 **Study site and population**

97 This study site was Kole hospital in the Sankuru District of Kasai-Oriental Province in
98 DRC. Land cover in the Sankuru District consists of tropical rainforest, savannah, and traditional
99 agricultural fields. Residents of the district are primarily subsistence farmers and hunters who
100 live in small villages that average 100 individuals, spread amongst small clearings in the forest
101 and small farming communes of extended families of less than 15 people (11). The research
102 was conducted jointly by the Institut National de Recherche Biomédicale (INRB) and the US
103 Army Medical Research Institute of Infectious Diseases (USAMRIID) at one of the two previous
104 WHO MPX study sites (1981-1986).

105 Admission to the “Monkeypox Isolation Ward” was based upon clinical diagnosis of
106 human MPXV infection by hospital staff. A clinically overt case of active MPX was defined as
107 having either (a) vesicular rash, with crops of vesicles of similar developmental stage in each

108 body region (regional monomorphism) typically first appearing on the face, hands, and feet
109 with centrifugal distribution (pox-like rash) or (b) fever of up to 39°C or a history of fever, rash,
110 lymphadenopathy, headache, malaise, or prostration in the past 2 weeks for which there is no
111 attribution. These patients were informed about the observational study and given the option
112 to participate by granting informed consent or if a minor, parental permission or ascent as the
113 situation required.

114 Patients were typically accompanied by family members, who provided basic care for
115 the patient. During this study family members stayed with the admitted patients within the
116 isolation compound where they prepared food for patients and family members.

117 **Compliance statement**

118 The study protocol was reviewed and approved by the Human Use Committee at the
119 USAMRIID (FY05-13) and the Headquarters, United States Army Medical Research and
120 Development Command Institutional Review Board (IRB) as well as the Ethics Committee at the
121 University of Kinshasa School of Public Health (KSPH). The study was conducted according to
122 the approved protocol and applicable U.S.A. federal, DOD and local regulatory requirements
123 and guidelines as well as in compliance with applicable Congolese law. The study was
124 conducted under the oversight of the Ministry of Health with appropriate guidance and
125 collaboration from the KSPH and the INRB. All personnel involved in the study had human
126 subjects protection training. Patient's privacy was respected in keeping with local cultural and
127 hospital standards. Reasonable care was taken to safeguard subject confidentiality and protect
128 medical information consistent with limitations of the hospital facility. Informed consent/assent

129 was obtained before any study procedure was performed. For children aged 0-11 years,
130 written informed consent was obtained from parent or guardian. For minors 12-17 years,
131 written assent was obtained as well as written parental/guardian informed consent. All were
132 given a copy of their signed informed consent/assent.

133 **Study design**

134 Patients who presented to hospital admitting with a presumptive diagnosis of MPX were
135 admitted to the physically separate infectious disease ward and offered an opportunity to be
136 evaluated for enrollment in the study but received the same treatment independent of
137 enrollment.

138 Once enrolled in this prospective observational study, continuation was based upon
139 obtaining positive results with Pan-OPXV PCR. All Pan-OPXV PCR positive patients were also
140 positive in the MPXV specific PCR. Positivity in any tissue was considered sufficient for inclusion
141 in the PCR positive group.

142 Once consent had been obtained, study personnel obtained a medical history;
143 performed a physical examination; recorded vital signs and weight; conducted a complete
144 lesion count; and collected specimens (blood, throat swabs, lesion (pox) swabs, and urine)
145 (scabs were collected when brought in by patient) for viral load PCR analysis, viral culture, and
146 hematology at enrollment and several time points throughout hospitalization: up to day 14, on
147 the day of discharge, and approximately day 75. A pregnancy test was administered on day 0 to
148 female participants of childbearing age but pregnant subjects were still allowed to enroll and
149 participate. Onsite physicians examined patients on day of admission and the following 3 days,
150 as well as the day of discharge and upon follow-up at day 75 (± 15 days). The duration of

151 hospitalization varied but was typically between 7 and 21 days. The severity of a given
152 symptom or sign (mild, moderate, severe) upon admission or during hospital stay was not
153 collected. As a substitute for this design flaw, we used number of symptoms and signs as a
154 “surrogate” of severity and labeled as level 1, level 2, level 3 or level 4 (death).

155 **Adjunctive medications administered to patients under direction of** 156 **hospital staff**

157 In recognition that many patients were hospitalized with fever which may include other
158 infectious processes in addition to or in lieu of MPX, patients were empirically treated with
159 amoxicillin for the first few days until the etiology of the fever was clearly established. If the
160 patients, had clinical suspicion of pneumonia or sepsis, the patients were treated with other
161 available antibiotics. Because the Congo River basin has very high endemicity for Falciparum
162 malaria, all patients with fever were treated empirically with appropriate antimalarial agents
163 until such time as sequential malaria smears confirmed there was no detectable parasitemia or
164 a full course of malaria treatment was completed if parasitemia was confirmed. A 10% solution
165 of Potassium Permanganate was used to disinfect skin in conjunction with bathing and other
166 hygienic measures to mitigate contact and fomite transmission of the infection.

167 Aspirin, acetaminophen and diclofenac were routinely given to reduce fever and treat
168 pain, including painful adenopathy which patients frequently experienced. Mebendazole was
169 given empirically on admission and continued for those who screened positive for evidence of
170 helminth infection.

171 One of the most significant interventions that the hospital staff provided was nutritional
172 support, which was given not only to the hospitalized patients, but also to those accompanying
173 family members who provided primary nursing care, hygienic measures and emotional support
174 to the hospitalized patients. When routine dietary intake was compromised by oropharyngeal
175 lesions and painful cervical adenopathy attempt was made by the hospital staff to provide
176 liquid food supplements and intravenous hydration.

177 **Lesion count methodology**

178 An indelible marker was used by nurses to divide the patient's body into nine
179 different skin regions and the oropharynx when lesions involved the mouth and/or throat,
180 for a total of 10 areas when the latter was involved. Total lesion count was determined by
181 summing all types of lesions. Results were audited by both the Medical Monitor and study
182 team quality control sections, utilizing the nurses case note books that included lesion
183 count by body area.

184

185 **Clinical laboratory procedures**

186 Clinical laboratory studies were done in compliance with USAMRIID's Clinical Laboratory
187 procedures. Hematology was performed using an AcT10 Hematology Analyzer by Beckman
188 Coulter, and urinalysis was done utilizing a Multistix 10 SG, by Siemens. Clinical chemistries
189 were performed using a Piccolo Point of Care General Chemistry panel (ALB, ALP, ALT, AMY,
190 AST, BUN, Ca, CRE, GGT, GLU, TBIL, TP) by Abaxis. HIV Ab were done at USAMRIID using the

191 Clinical Laboratory's routine HIV testing kit, Bio-Rad Laboratories Multispot HIV-1/HIV-2 Rapid
192 Test.

193 **DNA extraction and PCR analysis methodology**

194 DNA extraction with QIAamp DNA Mini Kit (Qiagen), inactivation of infectious virus by
195 incubation of specimen in extraction buffer at 56° C for 1 hr, and pan-orthopox real time
196 polymerase chain reaction (PCR) assays were performed using a Roche LightCycler and software
197 (24). All reagents were aliquoted into single test aliquots for up to 8 samples plus controls at
198 USAMRIID. Each patient assay used new reagent aliquots done the day specimens were
199 collected. Each assay included 6 standards covering the anticipated minimum and maximum
200 values. Positive controls (EDTA blood spiked with gamma irradiated monkeypox) and negative
201 controls (EDTA blood only) we're extracted with each assay run for specimens and results had
202 to fall within expected values for extraction and assay to be valid. The PCR assay included
203 samples to determine if contamination had occurred. In cases where controls did not meet
204 requirements tests were repeated with new reagents and standards.

205 **IgM and IgG methodology**

206 Serum IgM and IgG specific against anti-OPXV were detected by ELISA as previously
207 described (25). IgM and IgG assays were performed at 1:50 and 1:100 serum dilutions
208 respectively using purified vaccinia virus DryVax strain. Samples were determined positive or
209 negative based on the OD-COV value (Optical Density at 450 nm minus cutoff value of 3 times
210 standard deviation of averages from 5 negative controls.

211 **Benefits to the Kole Hospital and Community**

212 The study provided the following benefits to the Kole Hospital, staff and all patients:
213 funding of salaries of hospital staff involved with care of MPX patients, supplementation of
214 pharmaceutical and expendable supply budget, space available airlift of personnel and supplies,
215 including food/nutritional support for MPX patients and their family caregivers, and funding of
216 all medications provided to all MPX patients. The community had internet access with multiple
217 terminals using 5% of the study internet satellite, and hospital physicians had unlimited access.
218 Hospital clinicians had access to study clinical laboratory testing not routinely available at this
219 hospital, as well as supplementation to the clinical staff with additional physicians to insure
220 careful monitoring of disease and detection of treatable complications of illness.

221 A single payment of U.S. \$20.00 was provided to study patients who returned for the
222 follow up visit to compensate them for the blood draw. No other direct compensation was
223 provided to study patients.

224 **Statistical Methods**

225 All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC)
226 and Statistical Package R version 3.6.1. P-value less than 0.05 (typically ≤ 0.05) were statistically
227 significant.

228 Study Day 0 was defined as the admission day. Patients presented at various stages of
229 disease on the admission day. Thus for some analyses, the day of onset of rash was used to
230 synchronize timing. Positive days were counted forward from Day 0 and negative days were
231 counted backward from Day 0 after the rash onset. Patient age in years was computed as the
232 integer value (nearest rounded year) based on the date of birth and the date of signed

233 informed consent. Descriptive statistics were used to summarize the study results. PCR results
234 and total lesion counts were \log_{10} transformed for analyses. The age at admission was
235 categorized as <5, 5-11, and ≥ 12 years. Repeated measurement Analysis of Variance (ANOVA)
236 was used to compare means of total lesion count between different age groups. Repeated
237 measurement ANOVA also was used to compare the means of blood PCR viral load between
238 potential primary vs secondary cases or male vs female. Separate generalized estimating
239 equations (GEE) with cumulative logit models were used to evaluate associations between:
240 clinical symptoms/signs severity/illness severity/clinical syndromes severity (ordinal data) with
241 total lesions, PCR results, clinical observations and vital signs; and total lesions severity (ordinal
242 data) between vital signs, PCR results and clinical observations. Wilcoxon-Mann-Whitney test
243 by ranks was utilized for comparison of continuous variables between two group and Kruskal
244 Wallis Test for more than two groups. Fisher exact test or Chi-square test was used to compare
245 categorical variables. The p value in groups were adjusted by the stepdown Bonferroni
246 correction method.

247

248 **Results**

249 **Patient characteristics and demographics**

250 Two-hundred forty-four (244) patients were enrolled in the study based upon the
251 clinical diagnosis of MPXV infection. Of these, 216 patients had MPXV infection based upon
252 Pan-Orthopox PCR positive and MPXV specific PCR positive results. The 216 patients with active

253 MPXV infection were monitored and provided the data for this study. The first patient was
 254 enrolled 16 March 2007 and the last patient completed the study on 02 August 2011.

255 Patients were predominantly male (63.9%), age range 0-61 years (mean = 14, median =
 256 13) (Table 1). Of the 216 patients, 118 (54.6%) were age \geq 12. Four (4) patients reported history
 257 of smallpox vaccination, born during the years 1962-1972. However, 1 of 4 did not include the
 258 presence or absence of a scar notation. One patient was confirmed HIV positive based on Ab
 259 test; once recovered from acute MPXD, he was referred to a regional hospital for HIV
 260 treatment.

261 **Table 1. Demographics and exposure history**

Characteristic	Age Group			Total (N 216)
	< 5 (N = 31)	5-11 (N = 67)	\geq 12 (N = 118)	
Age at Admission (years), Mean (SD)	2 (1.3)	8 (2.1)	21 (8.4)	14 (9.9)
Gender, n (%)				
Female	19 (61.3%)	20 (29.9%)	39 (33.1%)	78 (36.1%)
Male	12 (38.7%)	47 (70.1%)	79 (66.9%)	138 (63.9%)
Marital Status, n (%)				
Married	0 (0%)	0 (0%)	35 (29.7%)	35 (16.2%)
Single	31 (100%)	67 (100%)	83 (70.3%)	181 (83.8%)
Family Exposure, n (%)				
Clean/Dressed Consumption Of Wild Game	17 (54.8%)	53 (79.1%)	86 (72.9%)	156 (72.2%)
Handled Uncooked, Freshly Butchered Meat	14 (45.2%)	47 (70.1%)	72 (61.0%)	133 (61.6%)
Meat Of Ground Squirrel	8 (25.8%)	30 (44.8%)	50 (42.4%)	88 (40.7%)
Initial Close Contact Of Infected Individual (Household)	17 (54.8%)	23 (34.3%)	46 (39.0%)	86 (39.8%)
Meat Of Monkey	9 (29.0%)	21 (31.3%)	52 (44.1%)	82 (38.0%)
Initial Mpx Contact With Blood, Body Fluids, Or Person With Tissue Or Secretions (Mpx Compatible Ill)	12 (38.7%)	12 (17.9%)	33 (28.0%)	57 (26.4%)
Dead Animal	3 (9.7%)	17 (25.4%)	27 (22.9%)	47 (21.8%)
Other Wild Game, Specify	8 (25.8%)	16 (23.9%)	22 (18.6%)	46 (21.3%)
Meat Of Gambian Rat Or Other Rodent	1 (3.2%)	5 (7.5%)	5 (4.2%)	11 (5.1%)
Multiple Exposures (\geq 2)	24 (77.4%)	67 (100%)	114 (96.6%)	205 (94.9%)

262

263 Exposure history

264 The most commonly reported family exposure was cleaning/dressing/consumption of
 265 wild game (n=156, 72.2%), followed by handling uncooked, freshly butchered meat (n = 133,
 266 61.6%) and eating squirrel meat (n=88, 40.7%) (Table 1). Importantly, 205 (94.9%) patients had
 267 2 or more possible exposures. Of the 11 individuals with a single exposure history, 4 were
 268 exposed to a household contact with MPXV infection, 4 consumed squirrel meat, 2 ate monkey
 269 meat and one cleaned, dressed, and consumed wild game (unspecified).

270 Clinical symptoms

271 The most common clinical complaint was rash (96.8%), followed by malaise (85.2%),
 272 sore throat (78.2%), lymphadenopathy (57.4%) and anorexia (50.0%) (Table 2A). The clinical
 273 symptom occurred at least once from admission day (study day 0) to study day 3.

274 **Table 2A. Descriptive tables of clinical symptoms in patients with acute monkeypox**
 275 **infection by age**

Organ-Systems	Clinical Symptom	Age Group						Total (N = 216)	
		<5 (N = 31)		5-11 (N =67)		≥ 12 (N = 118)		During Study Days 0-3	Discharge
		During Study Days 0-3	Discharge	During Study Days 0-3	Discharge	During Study Days 0-3	Discharge		
n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
General/Systemic	Chills	18 (58.1%)	1 (3.2%)	28 (41.8%)	1 (1.5%)	51 (43.2%)	0 (0%)	97 (44.9%)	2 (0.9%)
	Fever	1 (3.2%)	ND	0 (0%)	ND	0 (0%)	ND	1 (0.5%)	ND
	Malaise	27 (87.1%)	1 (3.2%)	58 (86.6%)	1 (1.5%)	99 (83.9%)	2 (1.7%)	184 (85.2%)	4 (1.9%)
	Sweats	7 (22.6%)	0 (0%)	12 (17.9%)	0 (0%)	24 (20.3%)	0 (0%)	43 (19.9%)	0 (0%)
Skin/Derm	Rash	31 (100%)	ND	66 (98.5%)	ND	112 (94.9%)	ND	209 (96.8%)	ND

Organ-Systems	Clinical Symptom	Age Group						Total (N = 216)	
		<5 (N = 31)		5-11 (N =67)		≥ 12 (N = 118)		During Study Days 0-3	Discharge
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
Lymphatics	Lymphadenopathy/ Adenopathy	18 (58.1%)	ND	40 (59.7%)	ND	66 (55.9%)	ND	124 (57.4%)	ND
HEENT	Conjunctiva redness, Eye pain, Eye discharge, etc.	4 (12.9%)	0 (0%)	6 (9.0%)	0 (0%)	10 (8.5%)	0 (0%)	20 (9.3%)	0 (0%)
	Ear Pain	0 (0%)	0 (0%)	5 (7.5%)	0 (0%)	10 (8.5%)	0 (0%)	15 (6.9%)	0 (0%)
	Hard Of Hearing	0 (0%)	ND	1 (1.5%)	ND	0 (0%)	ND	1 (0.5%)	ND
	Mouth/Throat Lesions	5 (16.1%)	ND	22 (32.8%)	ND	26 (22.0%)	ND	53 (24.5%)	ND
	Nasal Discharge/ Congestion	20 (64.5%)	3 (9.7%)	28 (41.8%)	2 (3.0%)	19 (16.1%)	2 (1.7%)	67 (31.0%)	7 (3.2%)
	Sore Throat	27 (87.1%)	1 (3.2%)	53 (79.1%)	1 (1.5%)	89 (75.4%)	0 (0%)	169 (78.2%)	2 (0.9%)
	Visual Changes	1 (3.2%)	0 (0%)	2 (3.0%)	0 (0%)	2 (1.7%)	0 (0%)	5 (2.3%)	0 (0%)
Cardiovascular	Chest Pain	0 (0%)	0 (0%)	1 (1.5%)	0 (0%)	10 (8.5%)	4 (3.4%)	11 (5.1%)	4 (1.9%)
	Swelling	1 (3.2%)	ND	0 (0%)	ND	0 (0%)	ND	1 (0.5%)	ND
Lungs	Cough	14 (45.2%)	0 (0%)	38 (56.7%)	0 (0%)	52 (44.1%)	4 (3.4%)	104 (48.1%)	4 (1.9%)
	Shortness of Breath	5 (16.1%)	1 (3.2%)	4 (6.0%)	0 (0%)	6 (5.1%)	0 (0%)	15 (6.9%)	1 (0.5%)
Gastrointestinal	Abdominal Pain	6 (19.4%)	2 (6.5%)	13 (19.4%)	1 (1.5%)	31 (26.3%)	8 (6.8%)	50 (23.1%)	11 (5.1%)
	Anorexia	20 (64.5%)	1 (3.2%)	34 (50.7%)	1 (1.5%)	54 (45.8%)	0 (0%)	108 (50.0%)	2 (0.9%)
	Diarrhea	3 (9.7%)	1 (3.2%)	2 (3.0%)	1 (1.5%)	5 (4.2%)	1 (0.8%)	10 (4.6%)	3 (1.4%)
	Dysphagia	6 (19.4%)	0 (0%)	22 (32.8%)	0 (0%)	26 (22.0%)	0 (0%)	54 (25.0%)	0 (0%)
	Vomiting	3 (9.7%)	0 (0%)	5 (7.5%)	0 (0%)	5 (4.2%)	0 (0%)	13 (6.0%)	0 (0%)
	Bleeding, Active, Various Sites	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (5.1%)	0 (0%)	6 (2.8%)	0 (0%)
Hematologic	Petechiae	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1.7%)	0 (0%)	2 (0.9%)	0 (0%)
	Back Pain	0 (0%)	0 (0%)	2 (3.0%)	0 (0%)	23 (19.5%)	0 (0%)	25 (11.6%)	0 (0%)
Musculoskeletal	Cervical Deformation	0 (0%)	ND	0 (0%)	ND	1 (0.8%)	ND	1 (0.5%)	ND

Organ-Systems	Clinical Symptom	Age Group						Total (N = 216)	
		<5 (N = 31)		5-11 (N =67)		≥ 12 (N = 118)		During Study Days 0-3	Discharge
		During Study Days 0-3	Discharge	During Study Days 0-3	Discharge	During Study Days 0-3	Discharge		
n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
	Joint Pain	0 (0%)	0 (0%)	5 (7.5%)	0 (0%)	15 (12.7%)	1 (0.8%)	20 (9.3%)	1 (0.5%)
	Muscle Pain	2 (6.5%)	0 (0%)	5 (7.5%)	0 (0%)	8 (6.8%)	0 (0%)	15 (6.9%)	0 (0%)
	Neck Stiffness	0 (0%)	0 (0%)	2 (3.0%)	0 (0%)	7 (5.9%)	0 (0%)	9 (4.2%)	0 (0%)
Neurologic	Dizziness	0 (0%)	ND	0 (0%)	ND	3 (2.5%)	ND	3 (1.4%)	ND
	Headache	0 (0%)	0 (0%)	16 (23.9%)	1 (1.5%)	35 (29.7%)	0 (0%)	51 (23.6%)	1 (0.5%)

276 During Study Days 0-3: The clinical symptom occurred at least once from the admission day (study day 0) to study day 3.

277

278 Physical examination findings or signs

279 The most common physical examination finding was classic MPXV skin lesions 215/216
 280 (99.5%) and lymphadenopathy (adenopathy) (98.6%) (Table 2B). MPXV mouth/throat lesions
 281 were seen in 28.7%) of patients. Abnormal lung sounds were detectable in 10.6% of patients.
 282 Hepatomegaly, splenomegaly or both were noted in 7.9% of patients. Bleeding was seen in
 283 2.3% of patients. The clinical sign occurred at least once from admission day (study day 0) to
 284 study day 3. Hyperthermia defined by the highest temperature of patients on the admission
 285 day; hypothermia defined by the first temperature of patients on the admission day.

286 **Table 2B. Descriptive tables of clinical signs in patients with acute monkeypox infection by**
 287 **age**

Organ-Systems	Clinical Sign	Age Group			Total (N = 216)
		<5 (N = 31)	5-11 (N =67)	≥ 12 (N = 118)	

		During Study Days 0-3	Discharge	During Study Days 0-3	Discharge	During Study Days 0-3	Discharge	During Study Days 0-3	Discharge
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
General/Systemic	Bed-bound	1 (3.2%)	0 (0%)	1 (1.5%)	1 (1.5%)	1 (0.8%)	0 (0%)	3 (1.4%)	1 (0.5%)
	Diminished Activity	26 (83.9%)	0 (0%)	49 (73.1%)	0 (0%)	74 (62.7%)	0 (0%)	149 (69.0%)	0 (0%)
	Hyperthermia	10 (32.3%)	2 (6.5%)	14 (20.9%)	0 (0%)	16 (13.6%)	0 (0%)	40 (18.5%)	2 (0.9%)
	Hypothermia	0 (0%)	0 (0%)	3 (4.5%)	0 (0%)	0 (0%)	0 (0%)	3 (1.4%)	0 (0%)
Skin/Derm	Dehydration	0 (0%)	0 (0%)	3 (4.5%)	0 (0%)	4 (3.4%)	0 (0%)	7 (3.2%)	0 (0%)
	Monkeypox Lesions	31 (100%)	20 (64.5%)	67 (100%)	45 (67.2%)	117 (99.2%)	94 (79.7%)	215 (99.5%)	159 (73.6%)
	Non-Specific Rash (Excludes MPX Lesions)	23 (74.2%)	15 (48.4%)	45 (67.2%)	26 (38.8%)	70 (59.3%)	58 (49.2%)	138 (63.9%)	99 (45.8%)
Lymphatics	Lymphadenopathy/ Adenopathy	31 (100%)	26 (83.9%)	67 (100%)	57 (85.1%)	115 (97.5%)	91 (77.1%)	213 (98.6%)	174 (80.6%)
HEENT	Conjunctival and Other Eye Lesion	2 (6.5%)	2 (6.5%)	6 (9.0%)	0 (0%)	6 (5.1%)	0 (0%)	14 (6.5%)	2 (0.9%)
	Mouth/Throat Lesions	7 (22.6%)	0 (0%)	25 (37.3%)	0 (0%)	30 (25.4%)	0 (0%)	62 (28.7%)	0 (0%)
	Nasal Discharge/Congestion/ Rhinorrhea/ Nasal Lesion	7 (22.6%)	2 (6.5%)	14 (20.9%)	1 (1.5%)	6 (5.1%)	0 (0%)	27 (12.5%)	3 (1.4%)
Cardiovascular	Abnormal Heart Rhythms	0 (0%)	0 (0%)	2 (3.0%)	0 (0%)	3 (2.5%)	0 (0%)	5 (2.3%)	0 (0%)
	Extremity Edema	1 (3.2%)	0 (0%)	0 (0%)	0 (0%)	5 (4.2%)	0 (0%)	6 (2.8%)	0 (0%)
	Heart Murmur	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.8%)	0 (0%)	1 (0.5%)	0 (0%)
Lungs	Abnormal Lung Sounds	11 (35.5%)	0 (0%)	9 (13.4%)	0 (0%)	3 (2.5%)	0 (0%)	23 (10.6%)	0 (0%)
Gastrointestinal	Abdominal Tenderness	0 (0%)	0 (0%)	3 (4.5%)	0 (0%)	12 (10.2%)	0 (0%)	15 (6.9%)	0 (0%)
	Hepatomegaly, Splenomegaly or Both	2 (6.5%)	0 (0%)	5 (7.5%)	0 (0%)	10 (8.5%)	1 (0.8%)	17 (7.9%)	1 (0.5%)
Hematologic	Bleeding	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (4.2%)	0 (0%)	5 (2.3%)	0 (0%)
Neurologic	Confused/Disoriented	2 (6.5%)	0 (0%)	2 (3.0%)	1 (1.5%)	1 (0.8%)	0 (0%)	5 (2.3%)	1 (0.5%)
	Lethargy/Stupor	2 (6.5%)	0 (0%)	4 (6.0%)	1 (1.5%)	6 (5.1%)	0 (0%)	12 (5.6%)	1 (0.5%)
Musculoskeletal	Musculoskeletal	0 (0%)	1 (3.2%)	1 (1.5%)	0 (0%)	4 (3.4%)	1 (0.8%)	5 (2.3%)	2 (0.9%)

288 During Study Days 0-3: The abnormal clinical sign occurred at least once from the admission day (study day 0) to study day 3. Hyperthermia
289 defined by the highest temperature of patients on the admission day; Hypothermia defined by the first tested temperature of patients on the
290 admission day.

291 **Duration of symptoms and signs**

292 Figure 1 shows the duration of symptoms and signs (S&S) from admission day in
293 patients with acute disease. As expected, at day of discharge the majority-of-patients still had
294 evidence of monkeypox skin lesions and lymphadenopathy. Most S&S lasted 3-5 days. The
295 sequence of symptom onset was not easily determined by this dataset.

296

297 **Disease severity categories**

298 Clinical illness groups are based upon the numbers of clinical S&S occurring on
299 admission as outlined at Supplemental Table S1. The matrix at Figure 2 shows the fitness of
300 clinical illness categories based upon clinical S&S severity.

301 The disease illness categories are: *level 1, level 2, level 3, and level 4 (fatal)*. We were not
302 able to delineate S&S that define survival versus death due to low statistical power. However,
303 we did find a group of S&S that defined the level 1, level 2, level 3 and level 4 (fatal) (Table 3A
304 and 3B) based upon the frequency of the S&S. Common symptoms included sore throat,
305 anorexia, cough, chills, nasal discharge & congestion, dysphagia, mouth/throat lesions,
306 headache, abdominal pain, sweats conjunctiva lesions, shortness of breath as well as such
307 physical findings or signs as diminished activity, nonspecific rash, mouth/throat lesions,
308 abnormal lung sounds, hepatomegaly/splenomegaly, lethargy/stupor, dehydration, and
309 confusion/disorientation.

310

311

312 **Table 3A. Comparison of clinical symptoms among monkeypox illness severity categories**

Organ-Systems	Clinical Symptom	Level 1	Level 2	Level 3	Adjusted P value	Raw P value
		(N = 99)	(N = 74)	(N = 40)		
		n (%)	n (%)	n (%)		
General	Chills	18 (18.2)	46 (62.2)	31 (77.5)	<.0001	<.0001
	Malaise	74 (74.7)	68 (91.9)	39 (97.5)	0.0043	0.0003
	Sweats	7 (7.1)	18 (24.3)	17 (42.5)	<.0001	<.0001
Skin/Derm	Rash	94 (94.9)	73 (98.6)	39 (97.5)	0.8391	0.4195
Lymphatics	Lymphadenopathy/Adenopathy	54 (54.5)	40 (54.1)	28 (70.0)	0.6044	0.2015
HEENT	Conjunctiva redness, Eye pain, Eye discharge, etc.	3 (3.0)	6 (8.1)	11 (27.5)	0.0019	0.0001
	Ear Pain	1 (1.0)	6 (8.1)	7 (17.5)	0.0095	0.0008
	Mouth/Throat Lesions	8 (8.1)	20 (27.0)	24 (60.0)	<.0001	<.0001
	Nasal Discharge/Congestion	13 (13.1)	25 (33.8)	27 (67.5)	<.0001	<.0001
	Sore Throat	60 (60.6)	68 (91.9)	38 (95.0)	<.0001	<.0001
	Visual Changes	2 (2.0)	0 (0)	3 (7.5)	0.2198	0.0440
Cardiovascular	Chest Pain	0 (0)	7 (9.5)	4 (10.0)	0.0139	0.0014
Lungs	Cough	28 (28.3)	47 (63.5)	27 (67.5)	<.0001	<.0001
	Shortness of Breath	0 (0)	6 (8.1)	7 (17.5)	0.0015	<.0001
Gastrointestinal	Abdominal Pain	7 (7.1)	32 (43.2)	9 (22.5)	<.0001	<.0001
	Anorexia	22 (22.2)	51 (68.9)	32 (80.0)	<.0001	<.0001
	Diarrhea	2 (2.0)	7 (9.5)	1 (2.5)	0.2663	0.0666
	Dysphagia	3 (3.0)	21 (28.4)	29 (72.5)	<.0001	<.0001
	Vomiting	1 (1.0)	7 (9.5)	4 (10.0)	0.0919	0.0115
Hematologic	Bleeding, Active, Various Sites	1 (1.0)	1 (1.4)	4 (10.0)	0.1708	0.0244
	Petechiae	0 (0)	0 (0)	2 (5.0)	0.2073	0.0345
Musculoskeletal	Back Pain	5 (5.1)	17 (23.0)	3 (7.5)	0.0133	0.0012
	Joint Pain	3 (3.0)	11 (14.9)	6 (15.0)	0.0607	0.0067
	Muscle Pain	0 (0)	10 (13.5)	5 (12.5)	0.0019	0.0001
	Neck Stiffness	0 (0)	3 (4.1)	6 (15.0)	0.0043	0.0003
Neurologic	Dizziness	1 (1.0)	1 (1.4)	1 (2.5)	0.8391	0.7739
	Headache	7 (7.1)	31 (41.9)	11 (27.5)	<.0001	<.0001

313 Statistics performed by Fisher exact test or Chi-square test with stepdown Bonferroni correction. Significant differences are highlighted by
 314 yellow (adjusted *p* value ≤ 0.05)

315 **Table 3B. Comparison of clinical signs among monkeypox illness severity categories**

Organ-Systems	Clinical Sign	Level 1	Level 2	Level 3	Adjusted P value	Raw P value
		(N = 99)	(N = 74)	(N = 40)		
		n (%)	n (%)	n (%)		
General/Systemic	Bed-bound	1 (1.0)	0 (0)	2 (5.0)	0.3991	0.1320
	Diminished Activity	47 (47.5)	61 (82.4)	38 (95.0)	<.0001	<.0001
	Hyperthermia	5 (5.1)	20 (27.0)	13 (32.5)	0.0001	<.0001
	Hypothermia	1 (1.0)	1 (1.4)	1 (2.5)	1.0000	0.7739
Skin/Derm.	Dehydration	0 (0)	1 (1.4)	6 (15.0)	0.0010	<.0001
	Non-Specific Rash (Excludes MPX Legions)	72 (72.7)	46 (62.2)	17 (42.5)	0.0328	0.0041
Lymphatics	Lymphadenopathy/Adenopathy	98 (99.0)	73 (98.6)	39 (97.5)	1.0000	0.7739
HEENT	Conjunctival and Other Eye Lesion	3 (3.0)	4 (5.4)	7 (17.5)	0.0659	0.0110
	Mouth/Throat Lesions	9 (9.1)	23 (31.1)	29 (72.5)	<.0001	<.0001

	Nasal Discharge/Congestion/Rhinorrhea/Nasal Lesion	2 (2.0)	5 (6.8)	19 (47.5)	<.0001	<.0001
Cardiovascular	Abnormal Heart Rhythms	1 (1.0)	0 (0)	3 (7.5)	0.1080	0.0216
	Extremity Edema	1 (1.0)	0 (0)	5 (12.5)	0.0107	0.0010
	Lungs	Abnormal Lung Sounds	2 (2.0)	10 (13.5)	11 (27.5)	0.0003
Gastrointestinal	Abdominal Tenderness	1 (1.0)	8 (10.8)	6 (15.0)	0.0118	0.0013
	Hepatomegaly, Splenomegaly or Both	2 (2.0)	4 (5.4)	11 (27.5)	0.0003	<.0001
Hematologic	Bleeding	1 (1.0)	1 (1.4)	3 (7.5)	0.3991	0.0998
Neurologic	Confused/Disoriented	0 (0)	0 (0)	4 (10.0)	0.0110	0.0011
	Lethargy/Stupor	1 (1.0)	1 (1.4)	9 (22.5)	<.0001	<.0001
Musculoskeletal	Musculoskeletal	1 (1.0)	0 (0)	4 (10.0)	0.0331	0.0047

316 Statistics performed by Fisher exact test or Chi-square test with stepdown Bonferroni correction. Significant differences are highlighted by
 317 yellow (adjusted p value ≤ 0.05)

318

319 **Monkeypox rash characteristics and body region distribution**

320 Figure 3 depicts the monkeypox lesion distribution pattern graphically. The graphic
 321 shows the mean distribution of all patients at peak lesion count (photographs of oropharyngeal
 322 lesions are cropped-consult authors for full de-identifiable photographs). Figure 4A shows the
 323 mean (\pm SE) total lesion count by age group and time from day of onset of classic MPXV rash.
 324 The mean lesion count was higher for the group <5 years compared to age groups 5-11 and ≥ 12
 325 years, although the difference was not statistically significant ($p = 0.1630$). Lesions peaked
 326 between days 5-8.

327 Lesion counts by body region over time is shown in Figure 4B. Lesion count peaked first
 328 on the head on Day 5. Figure 5 shows lesion progression from macule, papule, vesicle, pustule,
 329 umbilication, scabbing and desquamation for the hand. Progression from one phase to another
 330 occurs in order previously documented. Classic dogma holds that lesions in the same body
 331 region progress together as illustrated here.

332 Whether on day of admission or at maximum lesion count, a strong statistical
 333 significance was noted between illness categories and lesion counts independent of body
 334 location of lesions (Table 4A & B).

335

336 **Table 4A. Comparison of lesion count by location on day of admission among illness**
 337 **severity categories**

Body Location	Level 1	Level 2	Level 3	Level 4	Adjusted P value	Raw P value
	(N = 99)	(N = 74)	(N = 40)	(Death) (N = 3)		
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)		
Oral/Oropharyngeal Enanthem	1 (2.0)	4 (10.0)	6 (10.6)	29 (35.9)	<.0001	<.0001
Head	32 (44.3)	87 (113.1)	96 (117.6)	191 (102.2)	<.0001	<.0001
Arms	35 (54.0)	89 (100.6)	118 (181.0)	259 (89.8)	<.0001	<.0001
Hands	15 (32.7)	32 (43.5)	49 (101.7)	73 (58.2)	<.0001	<.0001
Trunk	27 (43.0)	77 (89.8)	95 (138.0)	313 (157.1)	<.0001	<.0001
Legs	62 (111.1)	154 (204.4)	217 (372.7)	374 (343.5)	<.0001	<.0001
Feet	12 (42.4)	17 (28.8)	22 (43.9)	49 (70.7)	0.0110	0.0110
Total Body	184 (300.9)	459 (547.1)	602 (885.8)	1288 (763.7)	<.0001	<.0001

338 Statistics performed by Kruskal Wallis Test with stepdown Bonferroni correction. Significant differences were highlighted by yellow (adjusted *p*
 339 value ≤ 0.05)

340 **Table 4B. Comparison of maximum lesion count by location among illness severity**
 341 **categories**

Body Location	Level 1	Level 2	Level 3	Level 4	Adjusted P value	Raw P value
	(N = 99)	(N = 74)	(N = 40)	(Death) (N = 3)		
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)		
Oral/Oropharyngeal Lesions	0 (1.1)	2 (3.5)	7 (12.6)	29 (35.9)	<.0001	<.0001
Head	38 (47.7)	106 (122.3)	147 (153.5)	527 (546.0)	<.0001	<.0001
Arms	42 (65.4)	102 (105.1)	149 (200.9)	771 (896.0)	<.0001	<.0001
Hands	19 (41.7)	38 (42.7)	75 (129.8)	222 (264.5)	<.0001	<.0001
Trunk	30 (45.7)	84 (91.9)	125 (190.5)	904 (924.2)	<.0001	<.0001
Legs	77 (128.7)	180 (208.0)	296 (438.3)	1284 (1431.2)	<.0001	<.0001

Feet	17 (65.6)	25 (35.9)	44 (67.1)	142 (133.1)	<.0001	<.0001
Total Body	223 (352.7)	537 (567.5)	843 (1098.6)	3879 (4210.2)	<.0001	<.0001

342 Statistics performed by Kruskal Wallis Test with stepdown Bonferroni correction. Significant differences were highlighted by yellow (adjusted *p*
343 value ≤ 0.05)

344

345

346 **Monkeypox infection associated lymphadenopathy**

347 The frequency of monkeypox induced lymphadenopathy was 98.6%, second only to
348 the frequency of the classic monkeypox rash itself. The distribution of lymphadenopathy is
349 depicted in Figure 6 (photographs are cropped-consult authors for full de-identifiable
350 photographs). The cervical region was most frequently afflicted at 85.6%; the second most
351 frequent area was the inguinal region 77.3%.

352 **Clinical laboratory findings**

353 The mean, median and range of values for each clinical laboratory tests are shown in
354 Supplemental Table S2. Figure 7A & 7B compares the median values of the 3 illness severity
355 categories-survivors--(death not included) and compares survivors (levels 1-3) vs. level 4
356 (death). Comparing those who died and survivors show statistically significant differences in the
357 alanine phosphatase (ALT) (90 vs 26 U/L; $p = 0.0224$, adjusted) and aspartate aminotransferase
358 (AST) (415 vs 48 U/L; $p = 0.0004$, adjusted). For CBC (complete blood count) variables, there
359 were no difference between survivors and fatal cases for any CBC variable. However, the WBC
360 and Neutrophil count show difference among the non-fatal categories. The platelet count was
361 $130 \times 10^3/\mu\text{L}$ in the fatal group vs $296 \times 10^3/\mu\text{L}$ among survivors ($p = 0.0102$, unadjusted). For
362 urine, the only statistically significant finding was elevated protein among illness severity level

363 1, 59 mg/dL (SD 65.3), level 2 category 88 mg/dL (SD 87.3), vs level 3 category 114 mg/dL (SD
364 108.3); $p = 0.0147$, adjusted (data not shown).

365

366

367 **IgM and IgG antibody responses**

368 A total of 200 patients serum samples were tested for IgM and IgG by ELISA. A total of
369 189 (94.5%) develop IgM responses and all 200 (100%) were either IgG positive at enrollment
370 or became positive during their hospitalization. The results of GEE with a cumulative logit
371 model showed that total lesion severity was not significantly associated with IgG antibody
372 responses (OR = 1.38, 95% CI: 0.72-2.62, $p = 0.3597$). However, the same model showed IgM
373 antibody responders were 5.09 times more likely to have higher lesion severity association than
374 IgM non-responders (OR = 5.09, 95% CI: 2.91-8.93, $p < 0.0001$). Further analyses of these
375 individuals will be the topic of a separate report.

376

377 **PCR results**

378 No significant change in MPX virus occurred between 1979 and 2010 based on full
379 length sequence of MPX from a patient. There were only 17 base changes out of 186,000 base
380 pairs between Zaire 79 and 136 even though they were isolated 30 years apart.

381 Blood, throat swabs, skin lesion and scab specimens were collected at scheduled
382 intervals per protocol to the follow up clinical visit at Day 75 and tested by PCR for confirmation
383 of MPXV infections. Figure 8 shows MPXV genomic material detection in blood and pharyngeal

384 swabs by PCR occurs before the onset of the classic rash onset. Therefore, care should be taken
385 when comparing PCR results with other variables because the maximum PCR viral load in blood
386 occurs near the first day of rash appearance, often before patients present to the hospital.
387 Unlike maximum lesion count maximum blood PCR viral load often could not be accurately
388 determined in this study—by the time most patients arrived at the hospital, viral load would
389 have already peaked. The graphs show a decrease in viral load over time for blood ($p < 0.0001$)
390 and pharynx ($p < 0.0001$). Generally, for specimens collected at the same time from the same
391 patient, the PCR viral load from throat is about 2000 genomes/mL higher than blood.

392 There was no difference in the level and decline over time for males and females for
393 blood ($p = 0.9079$) or pharynx ($p = 0.5208$) PCR copy numbers. The Wilcoxon-Mann-Whitney
394 test showed no significant differences in maximum PCR blood or maximum PCR throat swabs
395 results ($p = 0.4505$ and 0.8778 , respectively). Scabs contain significant quantities of MPXV
396 positive DNA until and including when they fall off. The concentration of MPXV in the scab is
397 several times the number of genomes in blood and throat. Viral infectivity in specimens was
398 not determined.

399

400 **Secondary household cases of Monkeypox**

401 For this analysis, patients who developed skin rash 14 days or longer after the first
402 household case of monkeypox were labeled secondary cases. Of the 216 patients in the study,
403 105 had family relationships. Twelve of the 44 families (27.27%) or 18 family members in this
404 study had secondary infections by this definition. The rate of secondary infection patients
405 compared to the total number of patients in the study is 8.34% (18/216). Patients diagnosed as

406 secondary cases had a lower mean total lesion count (386 vs 618) that peaked at day 4-5 and
407 healed at a faster rate than primary cases. Primary cases had a higher total lesion count (8619
408 vs 2448) that peaked at day 9-10 and healed more slowly compared to secondary cases ($p =$
409 0.1373). Classic primary and secondary cases are presented below.

- 410 • A hunter presented to the hospital with primary MPX and a fever of 7 days and
411 pox lesions present for 5 days with an admission lesion count of 427 that peaked
412 on lesion day 10 with 751 lesions. On admission the patient had severe
413 lymphadenopathy with blood MPX PCR viral load 2.1×10^5 genomes/ml, the
414 maximum value seen in this patient that slowly decreased to 1.5×10^3 by lesion
415 day (LD) 19. The patient was discharged after 34 days of hospitalization, much
416 longer than normal.
- 417 • A household member, presented with secondary MPX with enlarged cervical
418 lymph nodes (10 mm), positive blood MPX PCR viral load (4.8×10^3 genomes/mL)
419 and throat swab (1.4×10^6 genomes). Lesions were not present on admission and
420 first appeared on the 3rd hospital day (HD) LD 0 with 3 lesions that reached a
421 maximum on HD 6 (LD 4) with 21 lesions and blood genomes reached a
422 maximum on HD 5 with 1.3×10^5 genomes/ml that slowly decreased to 3.9×10^2
423 on discharge, HD 18. These 2 cases will be the subject of a more detailed report
424 to be published separately.

425 **Pregnancies and fetal outcomes.**

426 The course and outcome of four cases of maternal MPXV infection were described in a

427 previous publication (26). One of the four cases survived its mother's monkeypox infection.
428 Two pregnancies resulted in spontaneous abortions. The fourth suffered intrauterine death.
429 There was PCR and histopathologic evidence of a high monkeypox viral load in this fetus (26)
430 (Figure 9 A-C--photographs are cropped--consult authors for full de-identifiable photographs)

431 **Monkeypox virus infection death**

432 Three deaths occurred among the 216 patients in this cohort for which a detailed
433 accounting will be presented in a future publication. Two deaths occurred in the 5-11 year old
434 group, one in the <5 year old group and none in the ≥ 12 year old age group. The 3 deaths are
435 described briefly below:

436 **Fatal Case #1:** A gravely ill pediatric patient had 2091 lesions (VES 578, PUS 1375,
437 OMB 37) on admission at 6th day of fever and 5th day of rash. The patient's viral load
438 by PCR was 2.4×10^6 viral genomes/mL blood on admission. By day 2 lesions had
439 increased to 2447 and fever had resolved. The patient developed respiratory
440 distress and agonal breathing by 1700 and died at 2200 with elevated AST of 185 (2)
441 and ALP of 304. Figure 9 A-C shows lesions on maternal surface of placenta and
442 microscopic findings of placenta and infant skin lesions.

443 **Fatal Case #2:** A pediatric patient was admitted with complaints of fever for 3 days
444 with onset of pustular lesions. More than 1,000 vesicular and pustular lesions, along
445 with a few umbilicated lesions were observed. The clinical assessment was a child
446 with severe early-stage monkeypox, dehydration, ketoacidosis and proteinuria. MPX
447 viral genomes in blood were initially 10^6 genomes/mL and remained close to that
448 value until death (this case will be reported in detail in a later manuscript).

449 **Fatal Case #3:** A third pediatric patient, part of a family cluster of 4 patients was
450 admitted on the 4th day of fever and 3rd day after lesions developed. The patient had
451 a very high viral load (2×10^6) on admission, 601 lesions and died the next day with
452 very high liver transaminase values (AST = 865).

453 Death occurred in one pediatric patient from apparent respiratory illness 9 days after
454 discharge from hospital with monkeypox at which time the patient was disease free. The death
455 occurred at a location remote to the study site and investigators only became aware of the
456 child's death when the family did not return for the post-hospitalization follow-up visit. The
457 cause of death cannot be confirmed as MPX. Although, orthopoxvirus induced
458 immunosuppression is suspected as having contributed to the patient's death by investigators.
459 This case will be discussed in detail in a later publication.

460

461 **Comparisons between patients with fatal disease and survivors**

462 All patients who succumbed to MPX disease complained of malaise, sore throat and
463 anorexia compared to 50-84% of survivors but this difference did not reach statistical
464 significance. Except for the number of MPX lesions, there were no S&S that distinguished
465 between those who survived and those who died of MPX infection. Maximum lesion count was
466 significantly different between patients who survived and those who succumbed to MPX ($p =$
467 0.0025). Fatal cases had a significantly higher lesion counts (GM = 2,294, 95%CI: 79-66,842)
468 than surviving patients (GM = 195, 95% CI: 162-235). There was a significant difference in
469 maximum blood PCR genome levels between patients who succumbed and those who survived
470 MPXV infection ($p=0.0072$). Patients who died had significantly higher maximum PCR blood

471 genome levels (geometric mean (GM) = 9,204,937, 95%CI: 2.1×10^4 - 4.01×10^9) than surviving
472 patients (GM = 22,971, 95%CI: 1.4×10^4 - 3.8×10^4). The mean values for ALT and AST for patients
473 who died or survived were: 90 vs 26 U/L (p = 0.0224) and 415 vs 48 U/L (p = 0.0002) (p-values,
474 adjusted), respectively.

475 **Association analyses**

476 Figure 10 displays the Odds Ratio (OR) and p-values related to the association analyses.
477 The OR is one way to present the strength of association between risk factors/exposures and
478 outcomes. It represents the odds that an outcome will occur in the presence of a risk factor or
479 exposure, compared to the odds of the outcome in the absence of a risk factor or exposure. If
480 the 95% confidence interval for an OR includes 1, it means the results are not statistically
481 significant. Figure 10 shows the significant associations found in this analysis. Level of
482 consciousness (lethargy and/or stupor) has the highest ORs relative to its presence and disease
483 severity (ORs up to 24.34; $P < 0.0001$); followed by activity level (Incapacity) with ORs up to 6.32.
484 Details of certain subcategories are shown as additional Forest Plots in Supplemental materials
485 (Figures S1A-D).

486 **Discussion**

487 The most complete early description of human MPX infection comes from Bremen's
488 description of 47 cases between 1970-1979 in West and Central Africa and Ježek's 338 cases
489 between 1981-1986 from the two WHO MPX study sites in Zaire (opened after the eradication
490 of smallpox, reported in 1980) (27, 28). The epidemiologists described human MPX as closely
491 resembling, discrete ordinary-type smallpox or occasionally modified type smallpox. There have

492 been reports of several cases of morphologically atypical lesions in human MPX patients
493 including a previously reported case who was a stillborn infant from this study. No cases of
494 human MPX have yet been reported that resemble either confluent or hemorrhagic smallpox
495 either in the appearance of the exanthem or the rapidly fatal clinical course. The results of this
496 investigation reinforce prior observations of the severity and systemic nature of this infection,
497 while also highlighting opportunities to ameliorate clinical care and patient management.

498 The most characteristic and distinguishing characteristic of MPX from smallpox has been
499 the appearance of larger numbers of cases of MPX with painful, tender lymphadenopathy most
500 frequently noted in the cervical and submandibular regions, but also occurring as inguinal
501 adenopathy or generalized distribution, 98.6% of patients had lymphadenopathy. Our study
502 validates previous observations regarding lymphadenopathy occurrence in MPX as shown in
503 Figure 6. Enlarged lymph nodes may compress the airway leading to respiratory compromise.
504 Parental steroids may be indicated in these situations. Patients with multiple oropharyngeal
505 lesions may refuse to eat or drink as well and may become dehydrated. Intensive nursing care
506 and hydration would benefit these patients.

507 The PCR viral load from the throat were about 2000 genomes/mL more than blood
508 supporting the idea of swabbing the throat especially when MPXV infection is suspected but
509 blood PCR values are low or absent. As with smallpox, the scabs of MPV are highly
510 concentrated with virus even when it falls off. Maximum PCR values are known to correlate
511 with outcome in the lethal cynomolgus primate model including significant reductions with
512 successfully antiviral drug treatment (7, 29, 30). Maximum values occur early in the disease
513 course which can be accurately determined in controlled animal studies, however patients

514 entered the study after rash onset at a point at which the peak viremia had passed resulting in
515 the study failing to capture viral load peak levels for many patients. Thus, being admitted
516 several days after rash onset detracted from our ability to statistically validate maximum PCR
517 with certain disease indicators (consistent with early admissions having higher maximum PCR
518 values). Early disease seen in one patient supports the idea that maximum PCR values (a
519 measure of viral load) occur very early in the disease course. Patients admitted several days
520 after lesion onset are already past their maximum PCR value which explains why patients
521 admitted closer to the onset of their rash tended to have higher maximum detected PCR values.
522 For this study, the true maximum viral load was not determinable due to late admission of
523 patients with MPX. On the other hand, for most patients with non-fatal disease, maximum
524 lesion counts determined later in the course of the illness appeared to correlate with non-fatal
525 disease severity more clearly than observed maximal viral load.

526 Exposure to 2 or more wild animals was noted in 94.9% of patients [Table 1]. Bremen
527 reported the rate of interhuman transmission to susceptible household members as being 7.5%
528 in his series (27). In this report, we found the rate of secondary household transmission to be
529 8.3%. Three-quarters (72.7% of households with an index case of monkeypox did not suffer
530 secondary infections in our study.

531 Human MPXV infections result in a wide spectrum of illness ranging from mild to severe
532 and even death in this hospitalized population. Wide variation was observed in lesion counts.
533 The classic MPXV rash or lesion was observed in 99.5% of patients. The single patient with
534 MPX but without lesions was determined to have been vaccinated against smallpox decades
535 earlier. Because smallpox had largely disappeared from the developed world by the beginning

536 of the 20th Century, little is known or understood regarding extent of organ systems effected
537 directly by VARV, or how isolated impairment of for instance liver or renal function may have
538 contributed either to the morbidity of the illness or to also the mortality from infection. This
539 study used routine hospital laboratory testing to evaluate the occurrence of organ system
540 dysfunction and compare to clinical parameters of disease morbidity. Higher elevations of ALT
541 and AST did correlate with mortality, but the enzyme elevations were consistent only with
542 moderate acute liver injury and other parameters did not correlate with hepatic failure. While
543 dehydration was likely a major contributor to mortality, infection induced renal failure did not
544 appear to play a role in events leading to a patient's demise. Death in MPXV infections does not
545 appear to be caused by progressive multisystem failure based upon these observations and
546 evidence of multisystem failure is only seen as a pre-terminal event.

547 The predictors of poor prognosis included elevated AST and ALT; patients with these
548 findings should guide medical care providers toward intensive supportive care. Patients with
549 multiple oropharyngeal lesions and large cervical and other neck region lymphadenopathy who
550 are at greater risk of respiratory compromised, will not want to eat or drink as well and may
551 become dehydrated. Because motorized transportation is not available, many patients arrived
552 at the hospital, dehydrated, malnourished, anorexic, and fatigued, adding to the physiologic
553 stress of infection.

554 There were very few deaths in this case series, consequently we were not able to draw
555 firm conclusions regarding symptoms or physical findings that correlate with fatal infections.
556 The day of onset of symptoms prior to hospitalization was not collected, therefore, the
557 sequence of symptoms cannot be determined by this dataset, nor can symptoms duration be

558 precisely determined, although we can capture duration from the day of hospitalization.
559 Likewise, symptom severity was not collected. We used the number of symptoms as a
560 surrogate, based upon a symptoms vs signs matrix. We graded the illness using cumulative
561 totals of types of symptoms and numbers of individually identifiable signs. Using this arbitrary
562 grading system, we classified patients as level 1, level 2, level 3 and level 4 (fatal) (Table 3A and
563 3B) and present data reflective of the illness severity categories. Patients with higher total
564 number of S&S should be considered for hospitalization even if resources are limited. Patients
565 who are confused/disoriented/lethargic or stuporous had the highest Odds Ratios (OR's range
566 5.7-30.74) and should be provided immediate and intensive care. Frequently occurring
567 symptoms included sore throat anorexia, cough, fever, chills, nasal discharge and congestion,
568 dysphagia, mouth/throat lesions, headache, abdominal pain, sweats conjunctiva lesions,
569 shortness of breath. Frequently occurring physical findings were diminished levels of physical
570 activity, nonspecific rash, mouth/throat lesions, fever, abnormal lung sounds,
571 hepatomegaly/splenomegaly, lethargy/stupor, dehydration, confusion and or disorientation.
572 On a case-by-case basis, patients without these symptoms and signs could be considered for
573 triage to home treatment, providing hygiene, hydration and nutritional support are available
574 within the family unit. There is still much clinical work needed to refine and validate a grading
575 system to provide decision support regarding disposition and treatment of individual patients.
576 Based on the severity of disease, in young children, any grading system for triage, should take
577 the age of the patient into account as one of the major factors in determining the need and
578 benefit of hospital based care.

579 The case fatality rate of 1.4% (3/216) is markedly lower in this hospitalized cohort than
580 has occurred historically. The death of a pediatric patient occurred 9 days after being
581 discharged free from monkeypox disease. While being carried by its parents, the child
582 developed an acute respiratory infection during the long journey home and died 3 days after
583 arrival at their village. A case-fatality rate of 9.8% (33/338) was noted during a WHO sponsored
584 study in Zaire during 1981-1986 (26). A later study sponsored by the WHO during 1996-7 had a
585 case-fatality rate of 3.7% (27).

586 Fetal demise, the topic of a previous publication, occurred in 3 of 4 (75%) pregnancies
587 due to maternal MPXV infection [26]. In spite of confirmation of the relationship between
588 pregnancy and severe and fatal infection maternal MPXV infection was not always fatal to the
589 mother or the fetus.

590 Co-infections were frequent and included, chickenpox, malaria, microfilariasis,
591 giardiasis, ankylostomiasis, strongyloidiasis, filariasis species, and hookworm. Skin infections
592 were often present, including infected wounds. Several complications were noted such as,
593 caseation of the eye, keratitis, etc. A later publication will describe the MPXV-VZV co-infection
594 cohort that occurred during the course of this study.

595 A vast amount of data were collected during the conduct of this observational study
596 much of which cannot be adequately presented in this publication. Future publications will
597 include analysis of deaths associated with MPXV infections during this study, coinfections such
598 as chickenpox, complications observed among patients during this study, detail analyses of the
599 antibody data including peptide data, cytokine data, etc.

600 Recent efforts have facilitated FDA licensure of Jynneos, a non-replicating, third
601 generation vaccinia vaccine, for the prevention of smallpox and monkeypox (31, 32). Studies
602 are underway to examine the efficacy of this vaccine in prevention of human MPX (33).
603 Additionally, Tecovirimat (TPOXX, ST-246) and Brincidofovir were recently licensed by FDA for
604 the treatment of poxviral infections (34). Early treatment to prevent serious MPXV infection
605 should be investigated. As with other infectious diseases and intoxications, treatment before
606 or proximal to the onset of symptoms have the best outcomes.

607

608 **Acknowledgments**

609 We are most grateful to Dr. Therese Riu-Rovira for serving as medical monitor for the
610 study. Dr. Riu-Rovira is one of the two founding Missionaries of Christ Jesus, a Spanish Order of
611 Catholic Sisters, who have been managing the hospital and cases of human monkeypox disease
612 for over 30 years. We thank Diana Fisher for her expert and professional statistical
613 recommendations and support. Our sincerely thanks to Staff Sergeant Keith Kittle and Staff
614 Sergeant Jesse Kaplan for infrastructure buildout and maintenance.

615

616 **Kole Human Monkeypox Study Group:**

617 Jules Alonga, Guy Bilulu, Diana Blau, Jillybeth Burgado, Russ Byrne, Gary Carter,
618 Matthew S. Chambers, Jennifer Chapman, Didace Demba, Francis Devlin, Pierre Ewala, Kathleen
619 Farr, Robert Fisher, Steven Gire, Tim Haley, Lisa Hensley, Paul Hollier, Monique Jesionowski,
620 Jesse Kaplan, Keith Kittle, James Koterski, David Kulesh, Keith Iams, Donnat Mbale, Paul

621 Melstrom, Mitch Meyers, Eric Mucker, Gaston Mwema, Emile Okitolonda, Eddy Ortega, Kerry
622 Patterson, Nishi Patel, Sister Marisa Ramos, Sister Therese Ruis, Shirley Roach, Thomas
623 Robinson, Kate Rubins, John Schaber, Karen Sellers-Myers, David Sugerman, Max Teehee,
624 James Wadding, Sean Wilkes, Mark Withers.

625

626 **Conflicts of Interest**

627 The authors have no conflicts of interest.

628

629 **Disclaimer**

630 Opinions, interpretations, conclusions, and recommendations are those of the authors
631 and are not necessarily endorsed by DOD or HHS (CDC). Research on human subjects was
632 conducted in compliance with U.S. Department of Defense, federal, and state statutes and
633 regulations relating to the protection of human subjects and adheres to principles identified in
634 the Belmont Report (1979).

635

636 **Sponsor/Funding Source**

637 This study was funded by DTRA Contract W81XWH-06-2-004. Subcontract with Henry M.
638 Jackson Foundation (HMJF) for the Advancement of Military Medicine.

639 **References**

640 1. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu
641 Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593-7.

- 642 2. Organization WH. The global eradication of smallpox: final report of the Global Commission for
643 the Certification of Smallpox Eradication, Geneva, December 1979. . History of International Public
644 Health, no. 4. Geneva: World Health Organization; 1979.
- 645 3. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58(2):260-7.
- 646 4. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human
647 populations. Int J Epidemiol. 1988;17(3):643-50.
- 648 5. Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, et al. Monkeypox-induced
649 immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine
650 Immunol. 2007;14(10):1318-27.
- 651 6. Rimoin AW, Graham BS. Whither monkeypox vaccination. Vaccine. 2011;29 Suppl 4:D60-4.
- 652 7. Jahrling P HJea. Smallpox and related orthopoxviruses. Textbook of military medicine medical
653 aspects of biological warfare: Borden Institute, Washington DC; 2007.
- 654 8. Damon IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine.
655 2011;29 Suppl 4:D54-9.
- 656 9. Reynolds MG, Carroll DS, Karem KL. Factors affecting the likelihood of monkeypox's emergence
657 and spread in the post-smallpox era. Curr Opin Virol. 2012;2(3):335-43.
- 658 10. Jezek Z, Grab B, Dixon H. Stochastic model for interhuman spread of monkeypox. Am J
659 Epidemiol. 1987;126(6):1082-92.
- 660 11. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major
661 increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the
662 Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010;107(37):16262-7.
- 663 12. Bice S, Yeskey K. Poxvirus countermeasures during an emergency in the United States. Disaster
664 Med Public Health Prep. 2015;9(2):121-6.
- 665 13. Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al. Emergence
666 of Monkeypox - West and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep. 2018;67(10):306-
667 10.
- 668 14. Rezza G. Emergence of human monkeypox in west Africa. Lancet Infect Dis. 2019;19(8):797-9.
- 669 15. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human
670 monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis.
671 2019;19(8):872-9.
- 672 16. Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, et al. Reemergence of
673 Human Monkeypox in Nigeria, 2017. Emerg Infect Dis. 2018;24(6):1149-51.
- 674 17. Control ECfDPa. Risk assessment: monkeypox cases int he UK imprted by travelers returning
675 from Nigeria, 2018 [https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-monkeypox-cases-uk-imported-travellers-returning-nigeria2019)
676 [monkeypox-cases-uk-imported-travellers-returning-nigeria2019](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-monkeypox-cases-uk-imported-travellers-returning-nigeria2019) [
- 677 18. Health SMO. Confirmed imported case of monkeypox in Singapore
678 [https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-monkeypox-in-](https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-monkeypox-in-singapore2019)
679 [singapore2019](https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-monkeypox-in-singapore2019) [
- 680 19. Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, et al. Two cases of
681 monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018;23(38).
- 682 20. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of
683 monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350(4):342-50.
- 684 21. Prevention CfDCa. [Available from: [https://www.cdc.gov/media/releases/2021/s0716-confirm-](https://www.cdc.gov/media/releases/2021/s0716-confirm-monkeypox.html)
685 [monkeypox.html](https://www.cdc.gov/media/releases/2021/s0716-confirm-monkeypox.html).
- 686 22. Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull
687 World Health Organ. 2020;98(9):638-40.

- 688 23. Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW. Improving the Care
689 and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary
690 Biomedical and Smallpox Biodefense Research. *Viruses*. 2017;9(12).
- 691 24. Mucker EM, Hartmann C, Hering D, Giles W, Miller D, Fisher R, et al. Validation of a pan-
692 orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman
693 primate blood. *Virology*. 2017;14(1):210.
- 694 25. Karem KL, Reynolds M, Braden Z, Lou G, Bernard N, Patton J, et al. characterization of acute-
695 phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent
696 assay for detection of monkeypox infection during the 2003 North American outbreak. *Clin Diagn Lab*
697 *Immunol*. 2005;12(7):867-72.
- 698 26. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and
699 Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic
700 of Congo. *J Infect Dis*. 2017;216(7):824-8.
- 701 27. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-
702 79. *Bull World Health Organ*. 1980;58(2):165-82.
- 703 28. Jerek Z FF. Human monkeypox. *Monographs in Virology* 1988.
- 704 29. Huggins JW, Tikunova N. Antiviral drug development for the treatment of smallpox - status of
705 small-molecule therapeutics: A.S. Khan and G.L. Smith, WHO, Geneva; 2020.
- 706 30. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, et al. Exploring the
707 potential of variola virus infection of cynomolgus macaques as a model for human smallpox. *Proc Natl*
708 *Acad Sci U S A*. 2004;101(42):15196-200.
- 709 31. FDA. [https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox2021)
710 [replicating-vaccine-prevent-smallpox-and-monkeypox2021](https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox2021) [
- 711 32. Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 Efficacy Trial of Modified
712 Vaccinia Ankara as a Vaccine against Smallpox. *N Engl J Med*. 2019;381(20):1897-908.
- 713 33. Petersen BW, Kabamba J, McCollum AM, Lushima RS, Wemakoy EO, Muyembe Tamfum JJ, et al.
714 Vaccinating against monkeypox in the Democratic Republic of the Congo. *Antiviral Res*. 2019;162:171-7.
- 715 34. FDA. 2018 [Available from: [https://www.fda.gov/news-events/press-announcements/fda-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox)
716 [approves-first-drug-indication-treatment-smallpox](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox).
- 717 35. FDA. 2021 [https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox)
718 [smallpox](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox).

719

720 **Supplemental Table S1. Defining disease severity categories.**

721

722 Clinical symptom severity was defined as the number of any abnormal clinical symptom during study day 0-3 as
723 follows:

- 724 Grade 0: 0
- 725 Grade 1: 1-2
- 726 Grade 2: 3-4
- 727 Grade 3: 5-8
- 728 Grade 4: 9-11
- 729 Grade 5: ≥ 12

730

731 Clinical sign severity was defined as the number of any abnormal clinical sign during study day 0-3 as follows:

- 732 Grade 0: 0-1
- 733 Grade 1: 2-3
- 734 Grade 2: 4-5
- 735 Grade 3: 6-7
- 736 Grade 4: ≥ 8

737

738 Ill severity definition (4 level):

- 739 Level 1: Clinical symptom severity ≤ 2 and Clinical sign severity ≤ 2
- 740 Level 2: Clinical symptom severity ≥ 3 and Clinical sign severity < 3 or Clinical symptom severity < 3 and Clinical
741 sign severity ≥ 3
- 742 Level 3: Clinical symptom severity ≥ 3 and Clinical sign severity ≥ 3
- 743 Level 4: patients whose death were caused by acute monkeypox infection

744

745 Summary table for the clinical symptom severity and clinical sign severity during study day 0-3.

Symptom Sign	0	1	2	3	4	5	Total
4	0	0	0	1	4	1	6
3	0	2	1	21	10	3	37
2	1	16	35	56	7	1	116
1	5	22	19	7	0	0	53
0	0	1	0	0	0	0	1
Total	6	41	55	85	21	5	213

746

747

748

749 **Supplementary Table S2. Descriptive tables of Clinical laboratory values in patients with**
 750 **acute monkeypox infection on admission day.**


Laboratory Test (Unit)	N	Mean(SD)	Median	Min	Max	Normal Range	
						Male	Female
ALB (G/DL)	206	3 (0.5)	2.75	1.3	7.7	3.3 - 5.5	3.3 - 5.5
ALP (U/L)	202	123 (48.2)	112	0.5	304	53 - 128	42 - 141
ALT (U/L)	206	27 (22.6)	22	2.5	201	10 - 47	10 - 47
AMY (U/L)	205	78 (86.8)	61	2.5	1061	14 - 97	14 - 97
AST (U/L)	205	54 (77.4)	39	9	865	11 - 38	11 - 38
BUN (MG/DL)	187	8 (4.7)	7	0.5	32	7 - 22	7 - 22
CA (MG/DL)	205	9 (0.7)	8.9	2.7	10.2	8 - 10.3	8 - 10.3
CRE (MG/DL)	202	1 (0.4)	0.6	0.1	5.5	0.6 - 1.2	0.6 - 1.2
GGT (U/L)	206	47 (65.0)	30	2.5	703	5 - 65	5 - 65
GLU (MG/DL)	206	94 (21.7)	92	41	209	73 - 118	73 - 118
TBIL (MG/DL)	205	1 (0.3)	0.6	0.3	2.4	0.2 - 1.6	0.2 - 1.6
TP (G/DL)	206	8 (0.9)	7.8	3.2	13	6.4 - 8.1	6.4 - 8.1

751

752


Figures

Figure 1. The duration of clinical symptoms and signs




The mean of duration only included clinical symptoms and clinical signs present on the admission day.

Figure 2. Defining Monkeypox illness severity: clinical symptoms severity score and clinical signs severity score matrix




Clinical symptom/sign severity was defined as the number of any clinical symptom/sign during study day 0-3. Level 4 is the fatal group and the patient (cell 3-2) in this group was less than 1 year old with limited ability to explain his clinical symptoms.

Figure 3. Pattern of distribution of monkeypox lesions




The pattern of distribution of monkeypox lesions. The mean of lesions were counted on the day which the patients had the highest lesion count. One dot represents about 10 lesions per area (mean of lesion count/ percentage of Body Surface Area).

Figure 4. Change in total lesion count or lesion count by body location over time



(A) The mean with standard error bars of total lesion count by age group. Repeated measurement Analysis of Variance (ANOVA) showed there was no significant difference among the groups ($p = 0.2552$). (B) Distribution of mean of lesion counts for all patients by body location over time.


Figure 5. Change in lesion count on hands with time



Lesion progression from macule, papule, vesicle, pustule, umbilication (Umbilic), scabbing (scab) and desquamation (desquam).


◇ represent mean of count, — represent median of count, □ represent outliers, ↓ represent median day after onset of rash to get max lesion count for that specific rash morphology on hand.

Figure 6. The pattern of distribution of Monkeypox associated lymph node




Monkeypox associated lymph node distribution. The lymph node count and distribution were documented on the day patients had the most lymph nodes. One dot equals 10 lymph nodes or fraction thereof depending upon the count.

Figure 7A. Comparison of clinical laboratory among monkeypox illness severity categories



Comparison of clinical laboratory tests of patients with active monkeypox illness by severity categories on admission day. Statistics performed by Wilcoxon-Mann-Whitney test by ranks or Kruskal Wallis Test with stepdown Bonferroni correction. \square represent the first quartile to the third quartile of value in the group, $-$ represent median value in the group, \circ represent each value in the group.


Figure 7B. Comparison of CBC in patients with monkeypox illness severity categories



Comparison of complete blood count (CBC) of patients with active monkeypox illness by severity categories on the admission day. Statistics performed by Wilcoxon-Mann-Whitney test by ranks or Kruskal Wallis Test with stepdown Bonferroni correction.




□ represent the first quartile to the third quartile of value in the group, — represent median value in the group, ○ represent each value in the group.

Figure 8. Change in PCR count from blood, throat and scab with time




Mean of PCR count from blood, throat and scab (Log₁₀) with standard error bars (Unit: genomes/mL) over time.

Figure 9. The evidence of Monkeypox infection on Fetus and Placenta




(A) Maternal surface hemorrhages of placenta (B) There is diffuse epithelial positivity on placenta. 4X objective. (C) There is multifocal positivity in the fetal skin. 10X objectives. Panels B & C are Vaccinia Immunohistochemical examination of formalin fixed thin sections stained with H&E.

Figure 10. Significant associations found in the analysis




Forest Plot showing statistically significant associations. Odds ratio (OR), upper 95% confidence interval (UCL), and lower 95% confidence interval (LCL) were calculated using separate generalized estimating equations (GEE) with cumulative logit models, day after rash onset was adjusted as covariate. If a 95% confidence interval for an OR is >1, the odds of a given outcome are increased in the presence of a risk factor or exposure. If the 95% confidence interval for an OR is <1, it means the odds of a given outcome are decreased in the presence of a risk factor or exposure. Adjusted *p* value were calculated using stepdown Bonferroni correction if needed. Only significant results are showed here (*p* value ≤ 0.05).

Supplemental Figure S1A. Associations between monkeypox illness severity categories and other variables




Forest Plot showing associations between monkeypox illness severity categories and other variables on the admission day. OR, UCL and LCL were calculated by GEE with cumulative logit models, day after rash onset were adjusted as covariate and p value were adjusted by stepdown Bonferroni correction.

Supplementary Figure S1B. Associations between total lesion count severity with other variables




Forest Plot showing associations between total lesion severity and other variables on the admission day. OR, UCL, LCL were calculated using GEE with cumulative logit models, day after rash onset and age group were adjusted as covariate and p value were adjusted by stepdown Bonferroni correction.

Supplementary Figure S1C. Associations between HEENT syndrome severity with other variables



HEENT included following clinical symptoms or signs: Visual changes, Eye pain/discharge, Ear pain, Nasal discharge/congestion, Dysphagia, Sore throat, Conjunctive and other eye lesion, Nasal discharge/congestion/ rhinorrhea/nasal lesion, Mouth/throat lesions. The HEENT severity scores are based on the number of abnormal HEENT: Grade 0 (0), Grade 1 (1-2), Grade 2 (3-5), Grade 3 (6-7), Grade 4 (8-9).

Supplementary Figure S1D. Associations between GI syndrome severity with other variables



GI included following clinical symptoms or signs: Anorexia, Vomiting, Abdominal pain, Dysphagia, Diarrhea, Hepatomegaly, splenomegaly or both, Abdominal tenderness. The GI severity scores are based on the number of abnormal HEENT: Grade 0 (0), Grade 1 (1-2), Grade 2 (3-4), Grade 3 (5-8).